Reactome | Gilliland, DG

Schema > Person > Entries

Gilliland, DG Show undefined attributes

created	[InstanceEdit:4687055] Jupe, S, 2013-10-16
dbId	4687067
displayName	Gilliland, DG
firstname	D Gary
initial	DG
publications	[LiteratureReference:9673508] Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation [LiteratureReference:9699730] NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a [LiteratureReference:9673576] The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways [LiteratureReference:9673841] TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins [LiteratureReference:9672493] The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management [LiteratureReference:9699385] Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin [LiteratureReference:9696007] FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model [LiteratureReference:9695676] Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 [LiteratureReference:4687056] The retinoblastoma binding protein RBP2 is an H3K4 demethylase [LiteratureReference:9649425] Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD [LiteratureReference:8956068] Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells [LiteratureReference:9669059] Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 [LiteratureReference:9673500] Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent [LiteratureReference:9699355] Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia [LiteratureReference:9697898] The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3 [LiteratureReference:5211303] Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells [LiteratureReference:9700412] Activating mutations in ALK provide a therapeutic target in neuroblastoma [LiteratureReference:9691847] Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML [LiteratureReference:9699231] CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) [LiteratureReference:9671344] Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation [LiteratureReference:9691838] Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles [LiteratureReference:9672488] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [LiteratureReference:9657325] Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
schemaClass	Person
surname	Gilliland

Cite Us!